Multiple sclerosis, natalizumab, and PML: Helping patients decide

Cleveland Clinic Journal of Medicine

Volumn 78, Issue SUPPL. 2, 2011, Pages

  Rudick, Richard A ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NATALIZUMAB; VIRUS ANTIBODY;

ARTICLE; BLOOD; DIRECTIVE COUNSELING; HUMAN; IMMUNOLOGY; JC VIRUS; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, VIRAL; DIRECTIVE COUNSELING; HUMANS; IMMUNOLOGIC FACTORS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MULTIPLE SCLEROSIS;

EID: 84859883701     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.78.s2.05     Document Type: Article

References (28)

1. Weinshenker BG, Bass B, Rice GPA, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1999; 112: 133-146.
2. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39:285-294.
3. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43:655-661.
4. IFNB Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of multiple sclerosis: fi nal outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1995; 45:1277-1285.
5. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebocontrolled trial. Neurology 1995; 45:1268-1276.
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/ remitting multiple sclerosis. Lancet 1998; 352:1498-1504.
7. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fi ngolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362:387-401.
8. Cohen JA, Barkhof F, Comi G, et al. Oral fi ngolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362:402-415.
9. Gilenya [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011.
10. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical effi cacy outcomes. Lancet Neurol 2011; 10:338-348.
11. Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther 2011; 5:255-274.
12. Consortium of Multiple Sclerosis Centers (CMSC). Phase II study with ocrelizumab shows signifi cant reduction in disease activity. CMSC Web site. http://mscare.org/cmsc/index. php?option=com_ content&task=view&id=1081&Itemid=1465. Published October 15, 2010. Accessed August 26, 2011.
13. Tysabri [package insert]. South San Francisco, CA: Elan Pharmaceuticals, Inc.; 2011.
14. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354:899-910.
15. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
16. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007; 68:1390-1401.
17. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Effi cacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol 2009; 8:254-260.
18. Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol 2007; 62:335-346.
19. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multipls sclerosis. N Engl J Med 2006; 354: 911-923.
20. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354:924-933.
21. O'Connor PW, Goodman A, Kappos L. et al. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis [published online ahead of print May 4, 2011]. Neurology 2011; 76:1858-1865. pmid:21543733.
22. Update on Tysabri and PML. National Multiple Sclerosis Society Web site. http://www.nationalmssociety.org/news/news-detail/index. aspx?nid=2308. Published April 11, 2011. Updated May 23, 2011. Accessed June 22, 2011.
23. Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology 2011; 76:1697-1704.
24. Heesen C, Kleiter I, Nguyen F, et al. Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists. Mult Scler 2010; 16:1507-1512.
25. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361:1067-1074.
26. Jilek S, Jaquiery E, Hirsch HH, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a crosssectional and longitudinal study. Lancet Neurol 2010; 9:264-272.
27. Rudick RA, O'Connor PW, Polman CH, et al. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol 2010; 68:304-310.
28. Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratifi cation. Ann Neurol 2010; 68:295-303.